Literature DB >> 26154776

Fructooligosaccharides exert intestinal anti-inflammatory activity in the CD4+ CD62L+ T cell transfer model of colitis in C57BL/6J mice.

Fermín Capitán-Cañadas1, Borja Ocón2, Carlos José Aranda1, Andrea Anzola2, María Dolores Suárez1, Antonio Zarzuelo2, Fermín Sánchez de Medina2, Olga Martínez-Augustin3.   

Abstract

PURPOSE: Fructooligosaccharides (FOS) are used as functional foods due to their prebiotic effects. Intestinal anti-inflammatory activity has been established in most, but not all, studies in animal models of colitis, using mainly chemically induced inflammation. Our goal was to test the effect of FOS (degree of polymerization 2-8) in the chronic, lymphocyte-driven CD4+ CD62L+ T cell transfer model of colitis.
METHODS: Colitis was induced by transfer of CD4+ CD62L+ T cells to C57BL/6J Rag1(-/-) mice. FOS (75 mg day(-1)) was administered by gavage as a post-treatment. Three groups were established: non-colitic (NC), colitic control (C, CD4+ CD62L+ transferred mice treated with vehicle) and colitic+FOS (C+FOS, similar but treated with FOS). Mice were killed after 13 days.
RESULTS: Treatment of mice with FOS ameliorated colitis, as evidenced by an increase in body weight, a lesser myeloperoxidase and alkaline phosphatase activities, a lower secretion of proinflammatory cytokines by mesenteric lymph node cells ex vivo (IFN-γ, IL-17, and TNF-α), and a higher colonic expression of occludin (C+FOS vs. C, p < 0.05). Increased relative abundance of lactic acid bacteria was observed in FOS-treated mice (p < 0.05).
CONCLUSIONS: FOS exert intestinal anti-inflammatory activity in T lymphocyte-dependent colitis, suggesting it may be useful in the management of inflammatory bowel disease in appropriate conditions.

Entities:  

Keywords:  Alkaline phosphatase; CD4+ CD62L+ T cell; Colitis; Fructooligosaccharides; Inflammatory bowel disease; Prebiotic

Mesh:

Substances:

Year:  2015        PMID: 26154776     DOI: 10.1007/s00394-015-0962-6

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  44 in total

1.  Specific dietary oligosaccharides increase Th1 responses in a mouse respiratory syncytial virus infection model.

Authors:  Marcel A Schijf; Debby Kruijsen; Jacqueline Bastiaans; Frank E J Coenjaerts; Johan Garssen; Grada M van Bleek; Belinda van't Land
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

Review 2.  Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy.

Authors:  Anja Schirbel; Claudio Fiocchi
Journal:  J Dig Dis       Date:  2010-10       Impact factor: 2.325

Review 3.  Introducing inulin-type fructans.

Authors:  Marcel B Roberfroid
Journal:  Br J Nutr       Date:  2005-04       Impact factor: 3.718

Review 4.  Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose: experimental data.

Authors:  Nathalie M Delzenne; Patrice D Cani; Audrey M Neyrinck
Journal:  J Nutr       Date:  2007-11       Impact factor: 4.798

5.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

Authors:  J E Krawisz; P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

Review 6.  T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade.

Authors:  Dmitry V Ostanin; Jianxiong Bao; Iurii Koboziev; Laura Gray; Sherry A Robinson-Jackson; Melissa Kosloski-Davidson; V Hugh Price; Matthew B Grisham
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-11-25       Impact factor: 4.052

7.  Nondigestible oligosaccharides exert nonprebiotic effects on intestinal epithelial cells enhancing the immune response via activation of TLR4-NFκB.

Authors:  Mercedes Ortega-González; Borja Ocón; Isabel Romero-Calvo; Andrea Anzola; Emilia Guadix; Antonio Zarzuelo; Maria D Suárez; Fermin Sánchez de Medina; Olga Martínez-Augustin
Journal:  Mol Nutr Food Res       Date:  2013-09-03       Impact factor: 5.914

Review 8.  Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.

Authors:  Charlotte Hedin; Kevin Whelan; James O Lindsay
Journal:  Proc Nutr Soc       Date:  2007-08       Impact factor: 6.297

9.  Induction of alkaline phosphatase in the inflamed intestine: a novel pharmacological target for inflammatory bowel disease.

Authors:  Fermín Sánchez de Medina; Olga Martínez-Augustin; Raquel González; Isabel Ballester; Ana Nieto; Julio Gálvez; Antonio Zarzuelo
Journal:  Biochem Pharmacol       Date:  2004-12-15       Impact factor: 5.858

10.  Fermentable carbohydrate alters hypothalamic neuronal activity and protects against the obesogenic environment.

Authors:  Jelena Anastasovska; Tulika Arora; Gina J Sanchez Canon; James R C Parkinson; Kieran Touhy; Glen R Gibson; Nachiket A Nadkarni; Po-Wah So; Anthony P Goldstone; E Louise Thomas; Mohammed K Hankir; Jan Van Loo; Neena Modi; Jimmy D Bell; Gary Frost
Journal:  Obesity (Silver Spring)       Date:  2012-01-17       Impact factor: 5.002

View more
  10 in total

Review 1.  Gut Microbiota and IL-17A: Physiological and Pathological Responses.

Authors:  Banafsheh Douzandeh-Mobarrez; Ashraf Kariminik
Journal:  Probiotics Antimicrob Proteins       Date:  2019-03       Impact factor: 4.609

2.  Impact of dietary fructooligosaccharides (FOS) on murine gut microbiota and intestinal IgA secretion.

Authors:  Aditi Jangid; Shinji Fukuda; Tamotsu Kato; Masahide Seki; Yutaka Suzuki; Todd D Taylor; Hiroshi Ohno; Tulika Prakash
Journal:  3 Biotech       Date:  2022-02-02       Impact factor: 2.406

3.  Successive Fermentation of Aguamiel and Molasses by Aspergillus oryzae and Saccharomyces cerevisiae to Obtain High Purity Fructooligosaccharides.

Authors:  Orlando de la Rosa; Adriana Carolina Flores-Gallegos; Diana Muñíz-Márquez; Juan C Contreras-Esquivel; José A Teixeira; Clarisse Nobre; Cristóbal N Aguilar
Journal:  Foods       Date:  2022-06-17

4.  Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells.

Authors:  Valerio Rossini; Katarina Radulovic; Christian U Riedel; Jan Hendrik Niess
Journal:  J Vis Exp       Date:  2016-09-18       Impact factor: 1.355

5.  Activation of butyrate-producing bacteria as well as bifidobacteria in the cat intestinal microbiota by the administration of 1-kestose, the smallest component of fructo-oligosaccharide.

Authors:  Mikako Shinohara; Masaharu Kiyosue; Takumi Tochio; Seiji Kimura; Yasuhiro Koga
Journal:  J Vet Med Sci       Date:  2020-05-09       Impact factor: 1.267

6.  Konjac glucomannan polysaccharide and inulin oligosaccharide ameliorate dextran sodium sulfate-induced colitis and alterations in fecal microbiota and short-chain fatty acids in C57BL/6J mice.

Authors:  Chih-Hsuan Changchien; Cheng-Hsin Wang; Hsiao-Ling Chen
Journal:  Biomedicine (Taipei)       Date:  2021-09-01

Review 7.  Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends.

Authors:  Mohammad Al Mijan; Beong Ou Lim
Journal:  World J Gastroenterol       Date:  2018-07-07       Impact factor: 5.742

8.  Oligosaccharide-based quality evaluation of Atractylodis rhizome and a strategy for simplifying its quality control.

Authors:  Dan Zhuang; Jing Qin; Hui-Yang Wang; Yi Zhang; Chun-Yao Liu; Qing-Qing Ding; Guang-Ping Lv
Journal:  BMC Chem       Date:  2019-07-12

9.  Full Transcriptomic Response of Pseudomonas aeruginosa to an Inulin-Derived Fructooligosaccharide.

Authors:  José Manuel Rubio-Gómez; Carlos Molina Santiago; Zulema Udaondo; Mireia Tena Garitaonaindia; Tino Krell; Juan-Luis Ramos; Abdelali Daddaoua
Journal:  Front Microbiol       Date:  2020-02-20       Impact factor: 5.640

10.  Immunoregulatory Effects of Porcine Plasma Protein Concentrates on Rat Intestinal Epithelial Cells and Splenocytes.

Authors:  Cristina Hernández-Chirlaque; Carlos J Aranda; Borja Ocón; Javier Polo; Olga Martínez-Augustin; Fermín Sánchez de Medina
Journal:  Animals (Basel)       Date:  2021-03-13       Impact factor: 2.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.